GSK'963 is a potent and selective inhibitor of RIPK1 (receptor-interacting serine/threonine-protein kinase 1), making it a valuable tool compound in the study of necroptosis, a regulated form of inflammatory cell death. It is primarily used in preclinical research to investigate the role of RIPK1 in various disease models, particularly those involving inflammation and tissue injury. Applications include studies on neurodegenerative diseases such as Alzheimer's and ALS, where aberrant cell death pathways contribute to disease progression. It has also been employed in models of systemic inflammatory response syndrome (SIRS) and other acute inflammatory conditions to assess the therapeutic potential of blocking RIPK1-mediated signaling. Due to its high selectivity and favorable pharmacokinetic properties, GSK'963 helps validate RIPK1 as a drug target and supports the development of clinical candidates targeting necroptotic pathways.